Recent Research in Selective Cyclin-Dependent Kinase 4 Inhibitors for Anti-Cancer Treatment

被引：15

作者：

Liu, Ning ^{[1
]}

Fang, Hao ^{[1
]}

Li, Yanling ^{[2
]}

Xu, Wenfang ^{[1
]}

机构：

[1] Shandong Univ, Dept Med Chem, Sch Pharmaceut Sci, Jinan 250012, Shandong, Peoples R China

[2] Innermongolia Technol Univ, BaoTou Med Coll, Baotou 014020, Innermongolia, Peoples R China

来源：

CURRENT MEDICINAL CHEMISTRY | 2009年 / 16卷 / 36期

关键词：

Cell cycle; G1-phase; cyclin-dependent kinases; CDK4; tumor; selective inhibitors; anti-cancer agents; CELL-CYCLE; RETINOBLASTOMA PROTEIN; BIOLOGICAL-ACTIVITY; IN-VITRO; CRYSTAL-STRUCTURE; TYROSINE KINASES; CDK4; INHIBITORS; CANCER-CELLS; DRUG DESIGN; POTENT;

D O I：

10.2174/092986709789909611

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

It is well known that cyclins and cyclin-dependent kinases (CDKs) play essential roles in regulation of the cell cycle. In past two decades, the scientific researches suggest that the cyclin D1/ CDK4 complex is a key regulator of the transition through the G1 phase of the cell cycle. Moreover, deregulation of the cyclin D /CDK4 pathway has been identified in multiple tumor types. Thus, CDK4 is a genetically validated therapeutic target; hence, there has been a surge of interests in finding selective CDK4 inhibitors as anti-cancer agents. This review will give the recent progress in the studies of structure, functions of CDK4 and highly selective and potent CDK4 inhibitors.

引用

页码：4869 / 4888

页数：20

共 114 条

[21] Identification of selective inhibitors of cyclin dependent kinase 4 [J].

Carini, DJ ;

Kaltenbach, RF ;

Liu, J ;

Benfield, PA ;

Boylan, J ;

Boisclair, M ;

Brizuela, L ;

Burton, CR ;

Cox, S ;

Grafstrom, R ;

Harrison, BA ;

Harrison, K ;

Akamike, E ;

Markwalder, JA ;

Nakano, Y ;

Seitz, SP ;

Sharp, DM ;

Trainor, GL ;

Sielecki, TM .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (16) :2209-2211

[22] Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation [J].

Chen, HH ;

Wang, YC ;

Fann, MJ .

MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (07) :2736-2745

[23] Recent kinase and kinase inhibitor X-ray structures: Mechanisms of inhibition and selectivity insights [J].

Cherry, M ;

Williams, DH .

CURRENT MEDICINAL CHEMISTRY, 2004, 11 (06) :663-673

[24] Flavopiridol in the treatment of chronic lymphocytic leukemia [J].

Christian, Beth A. ;

Grever, Michael R. ;

Byrd, John C. ;

Lin, Thomas S. .

CURRENT OPINION IN ONCOLOGY, 2007, 19 (06) :573-578

[25] Crystal structure of human CDK4 in complex with a D-type cyclin [J].

Day, Philip J. ;

Cleasby, Anne ;

Tickle, Ian J. ;

O'Reilly, Marc ;

Coyle, Joe E. ;

Holding, Finn P. ;

McMenamin, Rachel L. ;

Yon, Jeff ;

Chopra, Rajiv ;

Lengauer, Christoph ;

Jhoti, Harren .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (11) :4166-4170

[26]

DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215

[27]

Dickson MA, 2009, CURR ONCOL, V16, P120

[28] Cycling to cancer with cyclin D1 [J].

Diehl, JA .

CANCER BIOLOGY & THERAPY, 2002, 1 (03) :226-231

[29] The regulation of E2F by pRB-family proteins [J].

Dyson, N .

GENES & DEVELOPMENT, 1998, 12 (15) :2245-2262

[30] Novel, potent and selective cyclin D1/CDK4 inhibitors:: Indolo[6,7-a]pyrrolo[3,4-c]carbazoles [J].

Engler, TA ;

Furness, K ;

Malhotra, S ;

Sanchez-Martinez, C ;

Shih, C ;

Xie, W ;

Zhu, GX ;

Zhou, X ;

Conner, S ;

Faul, MM ;

Sullivan, KA ;

Kolis, SP ;

Brooks, HB ;

Patel, B ;

Schultz, RM ;

DeHahn, TB ;

Kirmani, K ;

Spencer, CD ;

Watkins, SA ;

Considine, EL ;

Dempsey, JA ;

Ogg, CA ;

Stamm, NB ;

Anderson, BD ;

Campbell, RM ;

Vasudevan, V ;

Lytle, ML .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (14) :2261-2267

← 1 2 3 4 5 6 7 8 9 10 →